Research on the drugs used to treat cancer and how well they work. Covers immunotherapy, chemotherapy-free regimens, biosimilars, targeted drugs, and treatment costs.
Gambhir's work on multimodality molecular imaging has advanced nuclear medicine and healthcare. He has developed strategies to study gene and cell therapies, and his lab has more than 625 publications and over 40 patents pending.
Sanford Burnham Prebys Medical Discovery Institute has received four Padres Pedal the Cause collaborative grants to fund research projects in cancer and immunology. The projects aim to develop new insights into developing drugs and treatments designed to attack and kill cancer cells.
Researchers discover a protein that shields the PI3K pathway from targeted drugs, leading to improved efficacy with combination therapy. A new study reveals that blocking this protein restores cancer-killing potential in previously ineffective therapies.
Researchers have discovered a new type of small-cell lung cancer (SCLC) with distinct biological signatures, paving the way for developing personalized treatments. The discovery involves a novel transcription factor called POU2F3, which is expressed in a specific subset of SCLC tumors and may be targeted by specific drugs.
Researchers at EMBL screened over 1100 treatment conditions using a novel microfluidic device, discovering individualized cancer therapies for each patient. The device was tested on four patient biopsies, showing highly reproducible results and potential for personalized medicine.
A research team, led by OHSU physician-scientists, has discovered a drug compound that inhibits cancer cell movement and prevents them from spreading throughout the body. The compound was developed using a multidisciplinary approach, combining chemistry and biology to create a highly effective therapeutic.
Researchers at Texas Biomedical Research Institute have repurposed promising cancer chemotherapy drugs to target tuberculosis (TB), a deadly disease that kills four people every minute. The study found that these experimental drugs can reduce TB growth by 80% and also decrease inflammation and damage to the lungs.
A new study from the University of Pittsburgh School of Pharmacy found that concurrent opioid and benzodiazepine use increases the risk of opioid-related overdose by five-fold compared to opioid-only use. The risk decreases after 180 days of concurrent use, but is still elevated compared to opioid-only use.
A research team at the Walter and Eliza Hall Institute identified the molecular trigger for necroptosis, a type of controlled cell death that can lead to diseases like stroke, organ transplant injury, and kidney disease. The discovery could lead to new therapeutic targets for treating cancer and immune disorders.
Recent advances in cancer research focus on inhibiting key enzymes in glycolysis and glutaminolysis pathways to slow cancer cell proliferation. Several inhibitors are being tested in clinical trials, offering a promising new approach to combat cancer.
Monash researchers have created a computer model that can predict which combination of drugs will be most effective in treating triple negative breast cancer. The model, developed using genetic and treatment data from hundreds of patients, reveals a previously unknown combination of two drugs that may be successful.
Scientists discovered genetic causes of a group of related infant cancers that are targetable by existing drugs used to treat lung cancer and melanoma. Researchers identified mutations in the Epidermal Growth Factor Receptor (EGFR) and BRAF genes, which can be treated with afatinib and other targeted agents.
A novel combination of an epigenetic drug and a BCL-2 inhibitor has been identified as a promising target to reverse the development of high-risk neuroblastoma. The study found that this combination increases cell differentiation, allowing cancer cells to mature normally, making them more vulnerable to treatment.
Researchers found that glutamine is not a primary fuel for NK cells, but rather glucose. This discovery has significant implications for cancer therapies under development by pharmaceutical companies.
Researchers at FAU have successfully developed proteins that function like a shuttle to release medication directly in the body where it's needed. This breakthrough could enable targeted and tissue-specific administration of medication in future, potentially lowering doses and reducing side effects.
Researchers found that PARP inhibitors, such as rucaparib, showed promise in treating pancreatic cancer in patients with BRCA mutations. In a small study, 32% of patients experienced disease control after treatment.
Researchers found a link between calcitriol and reduced ovarian cancer progression by blocking smad signaling in tumor cells and supportive fibroblasts. The study opens a new potential avenue for treating ovarian cancer, with calcitriol already FDA-approved for other uses.
A recent study published in BMJ Open found that 7.6% of Britons reported experiencing preventable harm in primary care, with doctors often failing to take concerns seriously. The survey, conducted by University of Manchester researchers, highlights a significant divide between patient and clinician perspectives.
Researchers at Temple University Health System discover a dual synthetic lethality approach to eradicate cancer cells by inhibiting two backup repair pathways simultaneously. The strategy effectively narrows down the number of secondary repair pathways available, helping to ensure cancer cell eradication.
A new study found that CRISPR-Cas9 gene editing can activate the p53 protein, which reduces the efficiency of gene editing but also contributes to cancer cell growth. Researchers recommend further studies to improve safety for CRISPR-based therapies.
The University of Texas MD Anderson Cancer Center's Therapeutics Discovery team has developed a drug called IACS-10759, which targets metabolic vulnerability in cancer cells. The drug, an inhibitor of oxidative phosphorylation, shows promise for treating acute myeloid leukemia and solid tumors.
Researchers found that long-term viral suppression significantly reduces cancer risk in aging HIV-positive individuals, with lower rates seen in patients with sustained suppression compared to those with early or no suppression. The study highlights the importance of viral suppression in preventing cancer and may inform strategies for ...
Researchers have developed a new epigenetic drug that slows down cell growth in Mantle Cell Lymphoma by inhibiting the HDAC6 gene. The substance shows high efficacy in cultured cells, murine studies and patient-derived cells with minimal toxicity to healthy cells.
Vanderbilt University has received a five-year, $8.1-million grant from the National Cancer Institute to study small cell lung cancer, a highly aggressive and incurable tumor. The new center will use a multidisciplinary approach combining experimentation, mathematical modeling, and machine learning to develop new treatment avenues.
Researchers investigating combination therapies have encountered disappointing results. However, experts advocate for well-planned, randomized mid-stage trials to increase the chances of successful combined immunotherapies before Phase III trials.
Scientists have found that drug-resistant cancer cells have longer antennae-like structures called cilia, which can be targeted to restore sensitivity to treatment. Blocking growth of cilia restored cells' response to cancer drugs, with nearly doubling effectiveness.
Researchers at University of Groningen have elucidated the 3D structure of ASCT2, an amino acid transporter involved in various cancers. The study provides new insights into the protein's mechanism and potential targets for drug development.
A clinical trial shows that an immune checkpoint inhibitor can shrink tumors in nearly half of patients with advanced cutaneous squamous cell carcinoma. The drug, cemiplimab, works by blocking PD1, a surface receptor on T cells that shuts down immune response to cancer.
By replacing cysteine with selenocysteine, researchers have created biologically stable proteins that can survive longer in the human body. This breakthrough could lead to smaller, less frequent doses of medicine, lower healthcare costs, and fewer side effects for patients with cancer and other diseases.
The NCI-MATCH trial has released new findings on three arms of the trial, showing promise in patients with rare genetic changes. The study's results suggest that future studies could see more responses in populations with earlier-stage disease.
Researchers at Virginia Commonwealth University have discovered a mechanism that protects glioblastoma multiforme (GBM) stem cells from programmed cell death. The study found that protective autophagy is regulated by the gene MDA-9/Syntenin, and inhibiting this process can lead to cancer cell death.
A Phase II trial suggests that erdafitinib, an FGFR inhibitor, benefits patients with metastatic urothelial cancer harboring FGFR3 mutations. The therapy achieved a 40% overall response rate, including complete and partial responses, as well as stable disease in nearly half of patients.
Updated phase 1 clinical trial results of crizotinib against MET-amplified non-small cell lung cancer show a 40 percent response rate and 6.7-month median progression-free survival. The study defines new criteria to define 'highly MET-amplified' cancer, suggesting that crizotinib may benefit more patients than previously thought.
A Phase I trial shows ivosidenib, a protein inhibitor drug, is safe and effective for treating acute myeloid leukemia (AML) patients with IDH1 mutations. The study achieved an overall response rate of 41.6% and complete remission rates of 21.6%, with improved survival rates at 18 months compared to historical controls.
A phase 1 trial of ivosidenib against IDH1+ acute myeloid leukemia (AML) achieved an overall response rate of 41.9% and median progression-free survival of 8.2 months. Twenty-four percent of patients reached a complete response.
African-American men with advanced prostate cancer respond better to anti-androgen drugs and steroids than white men, according to a Duke University Medical Center study. The study suggests potential strategies for improving survival rates among black patients.
The study of SOCS1 and JAK proteins reveals a detailed structure that may guide the development of new cancer drugs. The protein pair is implicated in driving diseases including cancer and inflammatory conditions.
Researchers at the University of California San Diego School of Medicine have found that treatment with cirmtuzumab measurably inhibited the 'stemness' of CLL cells, allowing most patients to forego additional therapy for over eight months. The drug targets ROR1, a molecule exploited by cancer cells to promote tumor growth and spread.
Researchers developed a precision-medicine approach using patient-derived organoids to predict treatment responses in pancreatic cancer. The method identified specific gene signatures that can guide the selection of chemotherapy regimens, offering hope for improved survival rates and quality of life.
The US Department of Energy's Oak Ridge National Laboratory has developed a new method to produce actinium-227, a key radioisotope for the cancer drug Xofigo. This will ensure a sustainable supply of the drug, which is used to treat prostate cancer that no longer responds to hormonal or surgical treatment.
Researchers found that an antifungal medication can halt the growth of dormant cells within bowel tumours in mice. The study suggests that this drug could be effective in treating advanced bowel cancer by targeting drug-resistant cells.
Cancer cells use lipid molecules as fuel when blood supply is low, helping them evade antiangiogenic treatment. A new mechanism suggests that blocking lipid energy pathways could improve cancer treatment outcomes.
A novel data-driven approach called PanDrugs prioritizes cancer treatments based on patient genetic alterations. The method integrates pathway context and collective gene impact to provide therapeutic options for patients with limited druggable genes.
Researchers found that SHP2 inhibitors are effective against lung and pancreatic cancers, which share the same genetic error. The new class of drugs may help treat drug-resistant tumors by reverting cancer cells to being susceptible to other drugs.
A preclinical study found that combining soy lecithin with an NSAID increased anticancer properties and reduced gastrointestinal bleeding. The combination provided superior protection against colorectal cancer without the usual side effects, according to researchers at UTHealth.
Scientists have developed a new approach to cancer therapy by combining two synergistic drug components into a dimer, which can be loaded into polymeric nanotransporters at exceptionally high concentration. This method reduces side effects and improves transport and accumulation of drugs in tumors.
A Penn-led trial has shown that AZEDRA can significantly reduce cardiovascular side effects and stop tumor growth in patients with pheochromocytoma and paraganglioma. The drug is effective in controlling tumor size while also alleviating debilitating symptoms caused by excess hormone production.
Researchers from the University of Virginia have established new guidelines for scientists mapping out the body molecule by molecule to better understand how cells use metals. The guidelines aim to prevent pitfalls that could compromise work in X-ray crystallography, a technique used to reveal small molecular structures.
St. Jude Children's Research Hospital is launching St. Jude Global, a $100M initiative aiming to increase access to care for children with cancer globally within the next decade. The program focuses on education, capacity building, and research to improve childhood cancer survival rates worldwide.
A 5-year lifestyle counseling program for adult men was linked with a reduced risk of developing cancers related to overweight, diet, and smoking over 25 years. The study found that changes to a healthier diet and stopping smoking in adulthood can reduce the risk of some cancer forms.
A cancer patient with advanced ovarian cancer responded well to treatment with hydroxychloroquine and quinacrine, initially prescribed for an autoimmune disease. The case report suggests that repurposing antimalarial drugs may improve cancer outcomes.
Researchers developed a mouse model of luminal bladder cancer to study its therapeutic efficacy, focusing on checkpoint inhibitors and neo-antigens. The model revealed lower levels of immune cells in luminal tumors and differences in neo-antigen expression between subtypes.
The Los Angeles Cancer Surveillance Program, managed by Keck School of Medicine and USC Norris Comprehensive Cancer Center, has improved the understanding, prevention, and control of cancer for nearly 50 years. The program is one of the largest and most comprehensive cancer registries in the US.
A recent study by Mayo Clinic researchers found that the FDA-approved drug decitabine may be effective in treating triple-negative breast cancer. The study identified a subset of patients who could benefit from this therapy based on the presence of certain critical proteins.
A landmark study has delivered a final verdict on finasteride's impact on prostate cancer, finding it reduces risk without increasing mortality. Finasteride significantly lowers the risk of developing prostate cancer without causing an increased risk of dying from the disease.
USC researchers have identified a remedy to prevent lung metastasis in triple-negative breast cancer, which is the deadliest form of breast cancer. A novel solution uses a nanoparticle to deliver a medication directly to tumors, reducing toxic side effects.
Researchers found that combining erectile dysfunction drugs with the flu vaccine can reduce cancer spread by over 90% in a mouse model. The treatment works by blocking immune cells that suppress the immune system after surgery, allowing natural killer cells to fight cancer more effectively.
A small study of adults with pancreatic cancer reveals that patients with BRCA1 or BRCA2 gene mutations have poorer overall survival rates compared to those without the mutations. However, those with BRCA1 or BRCA2 had better survival rates with platinum-based chemotherapy.
Researchers developed a pill that can detect breast cancer in mice using near-infrared light, reducing the need for mammograms and minimizing radiation exposure. The imaging agent was found to bind specifically to cancer cells with high accuracy, paving the way for potential future applications.
Cleveland Clinic researchers found that lowering cholesterol levels can activate anti-tumor pathways in T-cells, leading to improved cancer-killing success. By reducing intracellular cholesterol, the cells' anti-cancer properties were enhanced.